Biopharmaceutical data analytics company IXICO (IXI) has announced it has been selected for an open-label Phase I/II dose finding study, emphasising it “reflects the confidence of our clients in the use of our services”. So what of a share price slightly ahead to 43.5p, but comparing to 58.5p in December?…

Biopharmaceutical data analytics company IXICO (IXI) has announced results for its year ended 30th September 2021 and the shares are currently more than 16% higher to 58.5p. However that compares to circa 84.5p when I previously wrote in October, so what’s the story now?…

Biopharmaceutical data analytics company IXICO (IXI) has made a trading update including that year ended 30th September 2021 EBITDA is “expected to be materially ahead of market expectations of £1.2 million and prior year (2020: £1.3 million)”. Why then is the share price little changed at circa 84.5p?…

Having been above 100p as recently as April, shares in biopharmaceutical data analytics company IXICO (IXI) are currently further lower at 72p despite a trading update including that “the company has successfully grown its pipeline of new opportunities”. So what’s going on?…